Cefotaxime: Difference between revisions
ClaireLewis (talk | contribs) No edit summary |
|||
(4 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: Third generation [[cephalosporin]] | *Type: Third generation [[cephalosporin]] | ||
*Dosage Forms: | *Dosage Forms: injectable solution, powder for injection | ||
*Common Trade Names: | *Dosage Strengths: injectable solution: 20, 40mg/mL; powder for injection: 500mg, 1g, 2g, 10g | ||
*Routes of Administration: IV, IM | |||
*Common Trade Names: Claforan | |||
==Adult Dosing== | ==Adult Dosing== | ||
Line 27: | Line 29: | ||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 1-2 hr | ||
*Metabolism: | *Metabolism: Partially metabolized in liver | ||
*Excretion: | *Excretion: Urine | ||
*Mechanism of Action: | *Mechanism of Action: Inhibits bacterial cell wall synthesis | ||
==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>== | ==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>== | ||
Line 157: | Line 159: | ||
*[[Antibiotics (Main)]] | *[[Antibiotics (Main)]] | ||
== | ==References== | ||
<references/> | |||
[[Category:Pharmacology]] [[Category:ID]] | |||
[[Category: |
Latest revision as of 21:51, 19 September 2019
General
- Type: Third generation cephalosporin
- Dosage Forms: injectable solution, powder for injection
- Dosage Strengths: injectable solution: 20, 40mg/mL; powder for injection: 500mg, 1g, 2g, 10g
- Routes of Administration: IV, IM
- Common Trade Names: Claforan
Adult Dosing
Pediatric Dosing
Special Populations
- Pregnancy:
- Lactation:
- Renal Dosing
- Adult
- Pediatric
- Hepatic Dosing
- Adult
- Pediatric
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life: 1-2 hr
- Metabolism: Partially metabolized in liver
- Excretion: Urine
- Mechanism of Action: Inhibits bacterial cell wall synthesis
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
References
- ↑ Sanford Guide to Antimicrobial Therapy 2014